PT  - JOURNAL ARTICLE
AU  - RA Pauwels
AU  - CG Lofdahl
AU  - NB Pride
AU  - DS Postma
AU  - LA Laitinen
AU  - SV Ohlsson
TI  - European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design
AID  - 10.1183/09031936.93.05101254
DP  - 1992 Nov 01
TA  - European Respiratory Journal
PG  - 1254--1261
VI  - 5
IP  - 10
4099  - http://erj.ersjournals.com/content/5/10/1254.short
4100  - http://erj.ersjournals.com/content/5/10/1254.full
SO  - Eur Respir J1992 Nov 01; 5
AB  - Chronic obstructive pulmonary disease (COPD) is a common disease in industrialised countries and responsible for a considerable morbidity and mortality. Cigarette smoking is the most important aetiological factor. The EUROSCOP trial aims at investigating the hypothesis that airway inflammation plays an important pathogenic role in the development of chronic obstructive airway disease in smokers. In cigarette smokers with poorly reversible airflow obstruction, the effect over 3 yrs of an inhaled glucocorticosteroid, budesonide 400 micrograms b.i.d., on the decline of lung function, measured as postbronchodilator forced expiratory volume in one second (FEV1), will be compared with that of placebo. The trial has been designed to detect a difference in yearly decline of at least 30 ml.year-1. The study is a parallel group, randomised, double-blind, multicentre study. Patients will be recruited from 47 centres in 12 countries in Europe. It will start with a run-in consisting of two 3 month periods. During the first 3 months, the patients will be offered a smoking cessation programme. All patients who have not stopped smoking during this period will enter the second half of the run-in where compliance with the dosage regimen will be tested. After these two periods, patients will be randomised to receive either inhaled budesonide, 400 micrograms b.i.d., or placebo for a period of 3 yrs.